VYX 0002
Alternative Names: VYX-0002Latest Information Update: 28 Sep 2024
At a glance
- Originator VICYCLX Labs
- Class Anti-infectives; Antibacterials; Small molecules; Urinary anti-infective agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacteraemia; Bacterial endocarditis; Methicillin-resistant Staphylococcus aureus infections; Staphylococcal infections; Urinary tract infections; Vancomycin-resistant Staphylococcus aureus infections; Ventilator associated pneumonia
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Bacterial-endocarditis in India (IV)
- 28 Sep 2024 No recent reports of development identified for preclinical development in Staphylococcal-infections in India (IV)
- 28 Sep 2024 No recent reports of development identified for preclinical development in Urinary-tract-infections in India (IV)